CY1113578T1 - 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια - Google Patents

2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Info

Publication number
CY1113578T1
CY1113578T1 CY20131100076T CY131100076T CY1113578T1 CY 1113578 T1 CY1113578 T1 CY 1113578T1 CY 20131100076 T CY20131100076 T CY 20131100076T CY 131100076 T CY131100076 T CY 131100076T CY 1113578 T1 CY1113578 T1 CY 1113578T1
Authority
CY
Cyprus
Prior art keywords
nitroimidazo
dihydro
oxazolia
general formula
provides
Prior art date
Application number
CY20131100076T
Other languages
English (en)
Inventor
Hidetsugu Tsubouchi
Hirofumi Sasaki
Hideaki Kuroda
Motohiro Itotani
Takeshi Hasegawa
Yoshikazu Haraguchi
Takeshi Kuroda
Takayuki Matsuzaki
Kuninori Tai
Makoto Komatsu
Makoto Matsumoto
Hiroyuki Hashizume
Tatsuo Tomishige
Yuji Seike
Masanori Kawasaki
Takumi Sumida
Shin Miyamura
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1113578T1 publication Critical patent/CY1113578T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Abstract

Η παρούσα εφεύρεση παρέχει μια 2,3-διυδρο-6-νιτροϊμιδαζο[2,1-b]οξαζολική ένωση αντιπροσωπευόμενη από τον ακόλουθο γενικό τύπο:
CY20131100076T 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια CY1113578T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
EP03754085A EP1555267B1 (en) 2002-10-11 2003-10-10 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES

Publications (1)

Publication Number Publication Date
CY1113578T1 true CY1113578T1 (el) 2016-06-22

Family

ID=32089299

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100076T CY1113578T1 (el) 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY2014041C CY2014041I1 (el) 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2014041C CY2014041I1 (el) 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Country Status (27)

Country Link
US (1) US7262212B2 (el)
EP (2) EP1555267B1 (el)
JP (1) JP4186065B2 (el)
KR (1) KR100723847B1 (el)
CN (4) CN101172981A (el)
AR (4) AR041198A1 (el)
AU (1) AU2003272979B2 (el)
BE (1) BE2014C053I2 (el)
BR (1) BRPI0314344B8 (el)
CA (1) CA2497569C (el)
CY (2) CY1113578T1 (el)
DK (1) DK1555267T3 (el)
ES (1) ES2400179T3 (el)
FR (1) FR14C0066I2 (el)
HK (2) HK1085463A1 (el)
HU (1) HUS1400046I1 (el)
LU (1) LU92517I2 (el)
MX (1) MXPA05003674A (el)
MY (1) MY139244A (el)
PL (3) PL404913A1 (el)
PT (1) PT1555267E (el)
RU (1) RU2326121C3 (el)
SI (1) SI1555267T1 (el)
TW (1) TWI347946B (el)
UA (1) UA83200C2 (el)
WO (1) WO2004033463A1 (el)
ZA (1) ZA200501033B (el)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
BR0313566A (pt) 2002-10-15 2005-06-21 Otsuka Pharma Co Ltd Composto de 4-nitroimidazol 1-substituìdo, método para preparar um composto de 4-nitroimidazol, método para preparar um composto de 4-nitroimidazol 1-substituìdo, derivado de 4-nitroimidazol, e, composto
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
WO2005042542A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
US7485727B2 (en) 2004-03-31 2009-02-03 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
EP1896453B1 (en) * 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
AU2006273355B2 (en) * 2005-07-28 2012-01-19 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising 2 , 3-dihydro-6-nitroimidazo [2 , 1-B] oxazole derivatives
TW201434467A (zh) * 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
BRPI0616667B1 (pt) 2005-10-06 2017-07-18 Nippon Soda Co. , Ltd. Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2640304A1 (en) * 2006-02-13 2007-08-23 Laboratoires Serono S.A. Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
CL2008002199A1 (es) * 2007-07-26 2009-10-23 Vitae Pharmaceuticals Inc Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
US20110281909A1 (en) * 2007-08-15 2011-11-17 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
EP2205585A1 (en) * 2007-10-16 2010-07-14 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
EP2229368A1 (en) 2007-12-11 2010-09-22 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
CA2712500A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009102460A2 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2274287B1 (en) * 2008-03-18 2016-03-09 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US7666864B2 (en) * 2008-03-26 2010-02-23 Global Alliance For Tb Drug Development Bicyclic nitroimidazole-substituted phenyl oxazolidinones
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PL2300461T3 (pl) * 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
BRPI0917394A2 (pt) * 2008-08-18 2019-09-24 Univ Yale moduladores de mif
WO2010021409A1 (en) 2008-08-21 2010-02-25 Dynamit Nobel Gmbh Explosivstoff - Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
CN102753558B (zh) * 2009-07-31 2014-10-15 全球结核病药物研发联盟 硝基咪唑并噁嗪及其在抗结核治疗中的应用
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
CA2769263C (en) * 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
JP5770096B2 (ja) 2009-10-26 2015-08-26 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
JP6532457B2 (ja) 2013-10-04 2019-06-19 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ ６−ニトロ−２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾール及びこれらの調製方法
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
WO2016063298A1 (en) * 2014-10-21 2016-04-28 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
US10227362B2 (en) 2015-01-29 2019-03-12 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
LT3275862T (lt) 2015-03-27 2020-09-25 Otsuka Pharmaceutical Co., Ltd. 1-(4-hidroksifenil)-4-(4-trifluormetoksifenoksi)piperidino arba jo druskos gamybos būdas
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
WO2017146246A1 (ja) 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
WO2018014863A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法
SI3668879T1 (sl) * 2017-08-16 2022-04-29 Glaxosmithkline Intellectual Property Development Limited Nove spojine
CN112236141A (zh) 2018-06-11 2021-01-15 大塚制药株式会社 包含德拉马尼的组合物
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
KR20050061473A (ko) 2005-06-22
EP1555267B1 (en) 2013-01-16
HUS1400046I1 (hu) 2017-04-28
TW200420568A (en) 2004-10-16
CN101172981A (zh) 2008-05-07
SI1555267T1 (sl) 2013-05-31
CY2014041I2 (el) 2016-07-27
PT1555267E (pt) 2013-01-29
CA2497569A1 (en) 2004-04-22
AU2003272979A1 (en) 2004-05-04
CN101255170A (zh) 2008-09-03
PL404913A1 (pl) 2013-09-30
JP4186065B2 (ja) 2008-11-26
AU2003272979B2 (en) 2009-07-23
RU2326121C2 (ru) 2008-06-10
CN102532162A (zh) 2012-07-04
BRPI0314344B1 (pt) 2019-11-26
US20060094767A1 (en) 2006-05-04
AR086485A2 (es) 2013-12-18
BRPI0314344B8 (pt) 2021-05-25
CN100366624C (zh) 2008-02-06
PL217919B1 (pl) 2014-09-30
CA2497569C (en) 2011-05-24
HK1085463A1 (en) 2006-08-25
RU2326121C3 (ru) 2021-09-17
HK1171018A1 (en) 2013-03-15
AR089950A2 (es) 2014-10-01
MXPA05003674A (es) 2005-06-08
EP2570418A3 (en) 2013-07-03
JP2004149527A (ja) 2004-05-27
KR100723847B1 (ko) 2007-05-31
CY2014041I1 (el) 2016-07-27
EP2570418A2 (en) 2013-03-20
FR14C0066I1 (el) 2014-10-17
AR041198A1 (es) 2005-05-04
BE2014C053I2 (el) 2022-08-30
TWI347946B (en) 2011-09-01
WO2004033463A1 (ja) 2004-04-22
AR091771A2 (es) 2015-02-25
UA83200C2 (en) 2008-06-25
PL376157A1 (en) 2005-12-27
EP1555267A1 (en) 2005-07-20
MY139244A (en) 2009-09-30
CN102532162B (zh) 2015-05-27
US7262212B2 (en) 2007-08-28
FR14C0066I2 (fr) 2015-05-22
ES2400179T3 (es) 2013-04-08
EP1555267A4 (en) 2010-08-18
DK1555267T3 (da) 2013-02-11
RU2005114017A (ru) 2006-01-20
BR0314344A (pt) 2005-07-12
CN1705670A (zh) 2005-12-07
ZA200501033B (en) 2006-06-28
PL409525A1 (pl) 2014-11-10
LU92517I2 (fr) 2014-10-13

Similar Documents

Publication Publication Date Title
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
ATE403429T1 (de) Spiropyrazol-verbindungen
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1114083T1 (el) Συνδυασμος μιας ενωσης της 5-φαινυλοθειαζολης ως αναστολεας της κινασης pi3 με ενα αντιφλεγμονωδες, βρογχοδιασταλτικο ή αντιισταμινικο φαρμακo
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
HRP20120323T1 (en) Diarylhydantoin compounds
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
UY28290A1 (es) Compuestos farmacéuticos novedosos
DE602004024798D1 (de) Herstellung von quetiapin
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
UY27250A1 (es) Fenil-heterociclil-cteres
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
NO20053208L (no) Metode for reduktiv dehalogenering.
BR0214445B1 (pt) processos para a produção de compostos.
GT200200250A (es) Compuestos hexaciclicos
HRP20030653B1 (en) Novel benzoylguanidine salt